Pluristem Therapeutics, Inc. :PSTI-US: Earnings Analysis: Q2, 2017 By the Numbers

Pluristem Therapeutics, Inc. reports financial results for the quarter ended December 31, 2016.


  • Summary numbers: Revenues of USD 0 million, Net Earnings of USD -6.61 million.
  • The company employs relatively high amounts of assets (with a turnover of 0x compared to peer median of 0.04x) while generating profit margins of -816.51% that are only about median among its chosen peers.
  • PSTI-US‘s earnings and EBITDA are both negative which suggest that P/E or Price/EBITDA are not meaningful to make this analysis between operating advantage (ROE) and growth expectations (as suggested by P/E or P/EBITDA).
  • Cash and Cash equivalents were down this period to 21.94 million compared to 43.65 million in the same period last year.
  • We consider the company to have a Quick & Able profile as it currently does not have any debt. In comparison, the median level of debt as percent of enterprise value for its peer group is currently 14.87%.
  • Of the 10 chosen peers for the company, only 6 of the stocks have an outstanding debt balance. Companies with no debt include ATHX-US, CBLI-US, UTHR-US and GERN-US.
  • Net income of -6.61 million this period compared to a net income of -6.32 million last period. This is a growth of -4.52% over the previous period. In comparison, the peer group grew at -4.52%

Access our Ratings and Scores for Pluristem Therapeutics, Inc.

Earnings Growth QOQ %
Cash & ST Investments

Access our Ratings and Scores for Pluristem Therapeutics, Inc.

Company Profile

Pluristem Therapeutics, Inc. is a biotechnology company engages in the provision of cell therapy development. It focuses on cell therapies for the treatment of diseases such as muscle injury, acute radiation syndrome, pulmonary arterial hypertension and others. Its products include PLacental eXpanded, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

CapitalCube does not own any shares in the stocks mentioned and focuses solely on providing unique fundamental research and analysis on approximately 50,000 stocks and ETFs globally. Try any of our analysis, screener or portfolio premium services free for 7 days. To get a quick preview of our services, check out our free quick summary analysis of PSTI-US.